Clinical observation and analysis of skin reactions caused by COVID‐19 vaccination

Abstract

The novel coronavirus disease 2019 vaccination is now an essential strategy for controlling the COVID-19 epidemic. This study included 132 cases of adverse skin reactions after the injection of COVID-19 vaccination from January 2021 to January 2022. The rate of adverse skin reactions after the 1st, 2nd, and 3rd doses of the COVID-19 vaccine were 52%, 40%, and 8% of total adverse skin reactions, respectively. The Urticaria-like rash was the most common manifestation of all adverse skin reactions, accounting for 40.15% of all adverse reactions. The Eczemalike rash was 27.27%. The rates of adverse skin reactions after vaccination with the COVID-19 vaccine in patients with a previous skin disease was 12.12%. Other rare skin adverse reactions after COVID-19 vaccination included herpes zoster, pityriasis rosea, erythema multiforme, chickenpox, herpes simplex, psoriasis, erythrodermatitis, arthus reaction, lichen planus recurrence, measles-like rash, frostbite rash, seborrhea,

Case Report: Fecal Microbiota Transplantation for the Treatment of Generalized Eczema Occurring After COVID-19 Vaccination

“… 10 One study showed that eczema-like rashes accounted for 27.27% of all adverse skin reactions. 11 Generalized eczema is an extremely rare condition with a complex mechanism of occurrence and development that is related to immune system dysfunction. The characteristics of a prolonged onset period, frequent recurrence, and difficulty in finding a cure seriously affect the quality of life for patients.…”

The onset or exacerbation of lichen planus following COVID-19 and vaccination against COVID-19

“…Dermatology Review/Przegląd Dermatologiczny 2023/4 et al reported recurrence of lichen planus after the first injection of COVID-19 vaccine in 1 patient as well as after the second injection in 1 patient [44].…”

“…Li i wsp. opisali także nawrót liszaja płaskiego po pierwszej dawce szczepionki przeciw COVID-19 u jednego pacjenta oraz po drugiej dawce u innego pacjenta [44].…”